SLS BIO Co., Ltd
SLS BIO Co., Ltd develops diagnostic technologies in South Korea. It offers pharmaceuticals quality control testing services, including pharmaceutical equivalence study, raw materials/finished drugs test, and other analysis testing services; and efficacy evaluation services, such as immune function-based efficacy evaluation and pharmacokinetics and toxicokinetics analysis services. In addition, i… Read more
SLS BIO Co., Ltd (246250) - Net Assets
Latest net assets as of : ₩- KRW
Based on the latest financial reports, SLS BIO Co., Ltd (246250) has net assets worth ₩- KRW as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩-) and total liabilities (₩-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SLS BIO Co., Ltd - Net Assets Trend (None–None)
This chart illustrates how SLS BIO Co., Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SLS BIO Co., Ltd (None–None)
The table below shows the annual net assets of SLS BIO Co., Ltd from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SLS BIO Co., Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SLS BIO Co., Ltd Competitors by Market Cap
The table below lists competitors of SLS BIO Co., Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Presidio Property Trust Inc. Series A Common Stock Purchase Warrants
NASDAQ:SQFTW
|
$13.44K |
|
Lotte Non-Life Insurance Co. Ltd.
KQ:000400
|
$13.45K |
|
Audioboom Group plc
LSE:BOOM
|
$13.46K |
|
178600
KO:178600
|
$13.46K |
|
CERUS (CU2.SG)
STU:CU2
|
$13.43K |
|
Albatros Acquisition Corporation Inc.
V:ALBT-P
|
$13.43K |
|
BEES4F
SA:BEES4F
|
$13.43K |
|
Development & Engineering Consultants
EGX:DAPH
|
$13.42K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SLS BIO Co., Ltd's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SLS BIO Co., Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SLS BIO Co., Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SLS BIO Co., Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $80,735,275,073
- Average return on equity (ROE) among peers: -13.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SLS BIO Co., Ltd (246250) | ₩- | N/A | N/A | $13.43K |
| NSN Co. Ltd (031860) | $102.59 Billion | 0.00% | 0.91x | $4.54 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.46 Billion | -32.51% | 0.43x | $77.93 Million |
| GeneMatrix Inc (109820) | $32.32 Billion | -3.06% | 0.22x | $21.53 Million |
| Genoray Co. Ltd (122310) | $11.35 Billion | 17.59% | 1.51x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $457.79 Billion | -16.14% | 0.26x | $147.96 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $30.10 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $27.02 Million |
| U2Bio Co., Ltd. (221800) | $33.84 Billion | 38.88% | 0.51x | $84.13 Million |
| Gencurix Inc (229000) | $8.20 Billion | -110.48% | 0.13x | $21.11 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $15.93 Million |